Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

I-Mab IMAB NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
63/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

I-Mab (IMAB) is a Biotechnology company in the Healthcare sector, currently trading at $2.88. It has a SharesGrow Score of 59/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Net income is $162M (loss), growing at +41%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+52.7 pp trend).

Balance sheet: total debt is $4M against $201M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 20.9 (strong liquidity). Debt-to-assets is 1.8%. Total assets: $213M.

Analyst outlook: 5 / 5 analysts rate IMAB as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 56/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).

IMAB SharesGrow Score Overview

79/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 56/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IMAB

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
IMAB: -225.9%/yr revenue is, +41%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet IMAB: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 20.9 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
56/100
IMAB: Gross margin is 100% (+52.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 56/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 5 / 5 analysts rate IMAB as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.595-6.79
Volume892.6K
Avg Volume (30D)1.85M
Market Cap$542.01M
Beta (1Y)1.46
Share Statistics
EPS (TTM)-4.46
Shares Outstanding$36.32M
IPO Date2020-01-17
Employees32
CEOXi-Yong Fu
Financial Highlights & Ratios
EBITDA$-373.45M
Net Income$-162.26M
Operating Income$-375.36M
Total Cash$173.4M
Total Debt$3.88M
Net Debt$-64.38M
Total Assets$212.68M
Price / Earnings (P/E)-0.6
Analyst Forecast
Rating ConsensusBuy
Analysts Covering5
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS44975P1030

Price Chart

Track all markets on TradingView
IMAB
I-Mab ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.60 52WK RANGE 6.79

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 BGNE
BGNE
BeiGene, Ltd.
$184.71
+0.49%
 ASND
ASND
Ascendis Pharma A/S
$249.84
+0.52%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 IMVT
IMVT
Immunovant, Inc.
$26.55
+5.69%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message